Esmolol contraindications: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) |
Ahmed Zaghw (talk | contribs) |
||
| Line 10: | Line 10: | ||
:*'''[[Heart block]]''' greater than first degree: Second- or third-degree [[atrioventricular block]] may precipitate or worsen [[bradycardia]] resulting in cardiogenic shock | :*'''[[Heart block]]''' greater than first degree: Second- or third-degree [[atrioventricular block]] may precipitate or worsen [[bradycardia]] resulting in cardiogenic shock | ||
:*'''[[cardiac arrest]]''' [see Warnings and Precautions (5.2)]. | :*'''[[cardiac arrest]]''' [see Warnings and Precautions (5.2)]. | ||
:*'''Sick sinus syndrome]]''': May precipitate or worsen bradycardia resulting in [[cardiogenic shock]] and [[cardiac arrest]] [see Warnings and Precautions (5.2)]. | :*'''[[Sick sinus syndrome]]''': May precipitate or worsen bradycardia resulting in [[cardiogenic shock]] and [[cardiac arrest]] [see Warnings and Precautions (5.2)]. | ||
:*'''Decompensated [[heart failure]]''': May worsen [[heart failure]]. | :*'''Decompensated [[heart failure]]''': May worsen [[heart failure]]. | ||
:*'''[[Cardiogenic shock]]''': May precipitate further cardiovascular collapse and cause [[cardiac arrest]]. | :*'''[[Cardiogenic shock]]''': May precipitate further cardiovascular collapse and cause [[cardiac arrest]]. | ||
Revision as of 18:50, 4 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Contraindications
BREVIBLOC (Esmolol Hydrochloride) is contraindicated in patients with:
- Severe sinus bradycardia: May precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest [see Warnings and Precautions (5.2)].
- Heart block greater than first degree: Second- or third-degree atrioventricular block may precipitate or worsen bradycardia resulting in cardiogenic shock
- cardiac arrest [see Warnings and Precautions (5.2)].
- Sick sinus syndrome: May precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest [see Warnings and Precautions (5.2)].
- Decompensated heart failure: May worsen heart failure.
- Cardiogenic shock: May precipitate further cardiovascular collapse and cause cardiac arrest.
- IV administration of cardiodepressant calcium-channel antagonists (e.g., verapamil) and BREVIBLOC in close proximity (i.e., while cardiac effects from the other are still present); fatal cardiac arrests have occurred in patients receiving BREVIBLOC and intravenous verapamil.
- Pulmonary hypertension: May precipitate cardiorespiratory compromise.
- Hypersensitivity reactions, including anaphylaxis, to esmolol or any of the inactive ingredients of the product (cross-sensitivity between beta blockers is possible).[1]
References
Adapted from the FDA Package Insert.